NAS:EDIT (USA)
Business Description
Editas Medicine Inc
NAICS : 325412
SIC : 2834
11 Hurley Street, Cambridge, MA, USA, 02141
Compare
Compare
Traded in other countries / regions
8EM.Germany
•
0IFK.UK
•
EDIT.USA
Description
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.34 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.16 | |||||
| Beneish M-Score | 0.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.7 | |||||
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -6.9 | |||||
| 3-Year FCF Growth Rate | -33.4 | |||||
| 3-Year Book Growth Rate | 18.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 5.15 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.41 | |||||
| 9-Day RSI | 58.5 | |||||
| 14-Day RSI | 59.8 | |||||
| 6-1 Month Momentum % | -9.97 | |||||
| 12-1 Month Momentum % | -76.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.67 | |||||
| Quick Ratio | 12.67 | |||||
| Cash Ratio | 12.43 | |||||
| Days Sales Outstanding | 6.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -584.44 | |||||
| Net Margin % | -580.16 | |||||
| ROE % | -33.76 | |||||
| ROA % | -27.5 | |||||
| ROIC % | -107.4 | |||||
| ROC (Joel Greenblatt) % | -443.49 | |||||
| ROCE % | -29.81 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 38.78 | |||||
| PB Ratio | 2.66 | |||||
| Price-to-Tangible-Book | 2.56 | |||||
| EV-to-EBIT | -4.35 | |||||
| EV-to-Forward-EBIT | -3.66 | |||||
| EV-to-EBITDA | -4.48 | |||||
| EV-to-Forward-EBITDA | -3.74 | |||||
| EV-to-Revenue | 25.42 | |||||
| EV-to-Forward-Revenue | 26.99 | |||||
| EV-to-FCF | -4.91 | |||||
| Price-to-Net-Current-Asset-Value | 3.45 | |||||
| Price-to-Net-Cash | 3.53 | |||||
| Earnings Yield (Greenblatt) % | -23.01 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:EDIT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 31.799 | ||
| EPS (TTM) ($) | -2.7 | ||
| Beta | 1.99 | ||
| Volatility % | 91.11 | ||
| 14-Day RSI | 59.8 | ||
| 14-Day ATR ($) | 1.318169 | ||
| 20-Day SMA ($) | 17.4875 | ||
| 12-1 Month Momentum % | -76.08 | ||
| 52-Week Range ($) | 9.59 - 73.025 | ||
| Shares Outstanding (Mil) | 68.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Editas Medicine Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||